Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.
News Medical on MSN37m
Researchers describe new molecular mechanisms linked to insulin resistanceInsulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high ...
Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr.
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus ...
During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback